Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: A two-year study

Acta Haematologica

Volumn 114, Issue 3, 2005, Pages 146-149

  Taher, Ali ^a,b   Sheikh Taha, Marwan ^c   Sharara, Ala ^a   Inati, Adlette ^b   Koussa, Suzane ^b   Ellis, Gareth ^d   Dhillon, A P ^d   Hoffbrand, A V ^d  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Chronic Care Center Hazmieh   (Lebanon)

^c LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Deferiprone; High dose; Iron chelation; Thalassemia major

Indexed keywords

ASPARTATE AMINOTRANSFERASE; DEFERIPRONE; FERRITIN; LIPOMED;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; MALE; PRIORITY JOURNAL; THALASSEMIA MAJOR; TIME SERIES ANALYSIS;

EID: 27544480823     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087888     Document Type: Article

References (21)

1. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S: Survival and causes of death in thalassaemia major. Lancet 1989;ii:27-30.
2. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573.
3. Hoffbrand AV, AL-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B: Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295-300.
4. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA: Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-423.
5. Taher A, Chamoun FM, Koussa S, Saad MA, Khoriaty AI, Neeman R, Mourad FH: Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. Acta Haematol 1999;101:173-177.
6. Barry M, Sherlock S: Measurement of liver iron content in liver biopsy specimen. Lancet 1971;1:100-103.
7. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN: Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
8. Scheuer PJ, Lefkowitch JH: Liver Biopsy Interpretation, ed 6. London, Saunders, 2000, p 274.
9. Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, Wonke B: Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995;91:224-229.
10. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F: Safety profile of the oral iron chelator deferiprone: A multicentre study. Br J Haematol 2000;108:305-312.
11. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, Schettini F, Stefano I, Tricta F: The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330-336.
12. Hoffbrand AV, Cohen A, Hershko C: Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:17-24.
13. Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani AT: Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992;82:460-466.
14. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G: Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 1995;332:918-922.
15. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, D'Ascola DG, Rizzo A, Midiri M: Deferiprone versus deferoxamine in patients with thalassemia major: A randomized clinical trial. Blood Cells Mol Dis 2002;28:196-208.
16. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F: Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-1587.
17. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, Frau MR, Faa G, Diana G, Dessi C: Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994;125:123-128.
18. Ardalan FA, Osquei MR, Toosi MN, Irvanloo G: Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: A retrospective cross-sectional study. BMC Gastroenterol 2004;4:17.
19. Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR: Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 2002;36:687-691.
20. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360:516-520.
21. Piga A, Gaglioti C, Fogliacco E, Tricta F: Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis. Haematologica 2003;88:489-496.